Celsion Corporation recently announced it is moving its headquarters from Columbia, MD to Princeton, NJ. An article published in yesterday’s Baltimore Sun asserts that the move is prompted by the lack of a labor pool in Maryland with experience in marketing, selling and distributing pharmaceuticals.
In addition to sponsoring clinical trials that are assessing its heat-sensitive drug, Thermodox, as a treatment for liver and breast cancer, Celsion is working in partnership with Philips Healthcare to develop a new focal drug delivery treatment for metastatic bone cancer. The method combines ThermoDox with Philips’ MR-guided focused ultrasound technology.
Click here to read the August 22, 2011 Baltimore Sun report.
Click here to read the April 2011 FUSF newsletter article about the Celsion/Philips collaboration
Click here to read the March 2010 FUSF newsletter in-depth profile of Celsion Corp.